论文部分内容阅读
目的:设计对照实验探讨孟鲁司特钠联合丙酸氟替卡松治疗小儿支气管哮喘的临床疗效及安全性。方法:以该院2013年3月至2015年5月接受治疗的100例支气管哮喘患儿为研究对象,随机将其均分为实验组、对照组,对照组患儿在常规治疗的基础上接受丙酸氟替卡松气雾剂辅助治疗;实验组患儿在常规治疗基础上接受孟鲁司特钠联合丙酸氟替卡松气雾剂辅助治疗,对两组患儿的临床治疗效果及安全性进行统计学分析研究。结果:实验组患儿治疗后第一秒用力呼气量(FEV1)、用力肺活量(FVC)以及呼气峰值流速(PEF)等均显著优于对照组,且实验组患者的临床总治疗有效率显著较高,不良反应发生率并不具有统计学差异。结论:在常规治疗基础上辅助以孟鲁司特钠联合丙酸氟替卡松综合疗法在治疗小儿支气管哮喘方面临床疗效显著且安全性较高,具有很好的临床意义。
Objective: To compare the clinical efficacy and safety of montelukast sodium and fluticasone propionate in the treatment of pediatric bronchial asthma. Methods: A total of 100 children with bronchial asthma who received treatment from March 2013 to May 2015 in our hospital were randomly divided into experimental group, control group and control group on the basis of routine treatment In the experimental group, the children were treated with the combination of montelukast sodium and fluticasone propionate aerosol on the basis of routine treatment, and the clinical effects and safety of the two groups were statistically analyzed the study. Results: FEV1, FVC and PEF of the experimental group were significantly better than those of the control group after treatment, and the total clinical effective rate in the experimental group Significantly higher, the incidence of adverse reactions does not have statistical difference. Conclusion: The combination of montelukast sodium and fluticasone propionate on the basis of routine treatment has a significant clinical effect and safety in the treatment of children with bronchial asthma, and has good clinical significance.